GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024. On June 4, three papers on LUMEVOQ®, the company’s gene therapy for Leber Hereditary Optic Neuropathy (LHON, will be